Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636817 · ClinicalTrials.gov registry record · Phase 2
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT01636817 is a Phase 2 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 239 participants.
The verdict
NCT01636817, a Phase 2 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly s.c. (subcutaneous, under the skin) injections to patients with active rheumatoid arthritis (RA) who are inadequate responders to anti-TNFa biologics and are on a stable background of methotrexate (MTX) therapy.
Interventions
- DRUG placebo
- DRUG NNC0109-0012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636817
The ClinicalTrials.gov registry entry for NCT01636817 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01636817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636817 about?
NCT01636817 is a clinical study titled "A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics". This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly s.c. (subcutaneous, under the skin) injections to patients with active rheum...
What is the current status of trial NCT01636817?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2012-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01636817?
The interventions under investigation include: placebo (DRUG), NNC0109-0012 (DRUG).
Who is sponsoring clinical trial NCT01636817?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.